Janssen’s Esketamine: US FDA Panel To Weigh Efficacy, REMS Restrictions For Treatment-Resistant Depression

FDA proposes requiring that healthcare facilities monitor patients for sedation and dissociative effects for two hours after self-administration; reliance on a randomized withdrawal trial as one of two adequate, well-controlled studies to support approval would be a first in the depression setting.

DEPRESSION miserable depressed , Depression and its consequences, Depressed emotions concept , alone in depression - Image

A US FDA advisory committee will weigh the persuasiveness of the efficacy data and the parameters of a restrictive Risk Evaluation and Mitigation Strategy (REMS) in considering whether Janssen R&D LLC’s esketamine should become the first drug approved for treatment-resistant depression in 10 years.

The Psychopharmacologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee will meet Feb. 12 to consider...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from US FDA Performance Tracker

More from Regulatory Trackers